Poxel (FRA:7PO) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:7PO Poxel SA FRA:7PO
44 GF Score
Price €0.20
GF Value €1.29
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Poxel FFO per Share?

FFO per Share only applies to REITs.

FRA:7PO
44GF Score
Poxel SA FRA:7PO
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Poxel (FRA:7PO) Overvalued in 2026?

Based on GuruFocus' analysis, Poxel stock appears to be undervalued. The current stock price of €0.20 is trading 84.8% below its estimated GF Value™ of €1.29. GuruFocus considers Poxel to be Possible Value Trap.

Key valuation signals for FRA:7PO:

  • FFO per Share:
  • GF Value™: €1.29 vs. price of €0.20 (84.8% below fair value)
  • GF Score™: 44/100 with 6 warning signs

No single metric tells the full story. See the FRA:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Poxel Business Description

Other Exchanges 0RA2:UKPOXEL:France
Address 259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
44GF Score

Get the complete analysis for FRA:7PO

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price
€1.29
GF Value